Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 31:11:647526.
doi: 10.3389/fonc.2021.647526. eCollection 2021.

B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy?

Wei Zhang  1   2 , Yu Qiu  1   2 , Xiaoli Xie  2 , Yao Fu  2 , Lijuan Wang  1   2 , Zhen Cai  3
Affiliations
Review

B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy?

Wei Zhang et al. Front Oncol. .

Abstract

T cells play a vital role in the immune responses against tumors. Costimulatory or coinhibitory molecules regulate T cell activation. Immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have shown remarkable benefits in patients with various tumor, but few patients have displayed significant immune responses against tumors after PD-1/PD-L1 immunotherapy and many have been completely unresponsive. Thus, researchers must explore novel immune checkpoints that trigger durable antitumor responses and improve clinical outcomes. In this regard, other B7 family checkpoint molecules have been identified, namely PD-L2, B7-H2, B7-H3, B7-H4 and B7-H6. The aim of the present article was to address the expression, clinical significance and roles of B7 family molecules in lymphoma, as well as in T and NK cell-mediated tumor immunity. B7 family checkpoints may offer novel and immunotherapeutic strategies for patients with lymphoma.

Keywords: B7-H2; B7-H3; B7-H4; B7-H6; PD-L1; PD-L2; lymphoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
mRNA expression levels of B7 family molecules in DLBCL. This heatmap shows the expression of the 10 genes of B7 family members in normal tissue and DLBCL: normal tissue from the whole blood cells of GTEx (n = 337), DLBCL from TCGA DLBCL (n= 47). The data were obtained from UCSC Xena and were log2 transformed and were analyzed by Mann-Whitney U test. * 0.01<P<0.05, ** 0.0001=<P<0.01, *** P<0.0001.
Figure 2
Figure 2
The regulatory mechanisms and function of PD-L1/PD-L2 in lymphoma.
Figure 3
Figure 3
The regulatory mechanisms and therapies targeting B7-H3.
Figure 4
Figure 4
The regulatory mechanisms and therapies targeting B7-H4.
Figure 5
Figure 5
The regulatory mechanisms and therapies targeting B7-H6.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sun X, Zhao J, Ma L, Sun X, Ge J, Yu Y, et al. . B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cells. Invest New Drugs (2020) 39(1):24–33. 10.1007/s10637-020-00976-5 - DOI - PubMed
    1. Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol (2019) 20(11):1425–34. 10.1038/s41590-019-0512-0 - DOI - PubMed
    1. Wang C, Feng H, Cheng X, Liu K, Cai D, Zhao R. Potential Therapeutic Targets of B7 Family in Colorectal Cancer. Front Immunol (2020) 11:681. 10.3389/fimmu.2020.00681 - DOI - PMC - PubMed
    1. Kaur G, Janakiram M. B7x-from bench to bedside. ESMO Open (2019) 4(5):e000554. 10.1136/esmoopen-2019-000554 - DOI - PMC - PubMed
    1. Zhang L, Mai W, Jiang W, Geng Q. Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Front Oncol (2020) 10:594558. 10.3389/fonc.2020.594558 - DOI - PMC - PubMed